Enterprise AI Analysis
PathOrchestra: Pioneering AI in Digital Pathology
A versatile foundation model trained on nearly 300K slides, demonstrating clinical readiness across over 100 diverse tasks for enhanced diagnostic accuracy and efficiency.
The complexity and variability of high-resolution pathological images present significant challenges in computational pathology, requiring large-scale, intensely annotated datasets for traditional AI methods.
PathOrchestra leverages self-supervised learning on extensive, diverse data (287,424 slides from 21 tissue types across three centers) to overcome these limitations, providing a generalizable and robust AI solution that reduces reliance on manual annotation.
This model achieves over 0.950 accuracy in 47 critical tasks, setting new benchmarks for real-world applications in screening, diagnosis, lesion identification, multi-cancer subtyping, biomarker assessment, gene expression prediction, and structured pathology reporting.
Transforming Pathology Diagnostics
PathOrchestra's foundational capabilities redefine efficiency and accuracy in computational pathology, delivering significant advancements across a multitude of clinical applications.
0
WSIs Processed for Training
0
Clinical-Grade Tasks Evaluated
0
ROI Images Analyzed
0
Tasks Achieving >0.950 Accuracy
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Slide Preprocessing
Pan-cancer Classification
Lesion Identification
Subtype Classification
Biomarker Assessment
Gene Expression Prediction
Report Generation
PathOrchestra excels in foundational preprocessing tasks, crucial for clinical workflow efficiency and diagnostic accuracy. Its robust capabilities minimize manual intervention and ensure high-quality data for subsequent analysis.
0.980+
Average Accuracy in Key Preprocessing Tasks
| Task | PathOrchestra Performance (ACC/F1) | Key Benefit |
|---|---|---|
| Image Identification | ACC/F1 > 0.970 | Ensures correct initial analysis. |
| Staining Recognition (H&E/IHC) | ACC/F1 > 0.970 | Automates lab workflow, ensures correct staining interpretation. |
| Bubble/Adhesive Detection | ACC/F1 > 0.980 | Removes artifacts, improves diagnostic reliability. |
| Magnification Discrimination | ACC/F1 > 0.970 | Standardizes image scale for consistent analysis. |
PathOrchestra demonstrates robust generalization in pan-cancer classification, accurately distinguishing multiple cancer types across diverse data sources and preparation methods. This capability is vital for early detection and improving diagnostic accuracy.
0.988 AUC
Peak AUC in 17-Class Pan-Cancer Classification
| Dataset | Cancer Types | PathOrchestra Performance (AUC) | Strategic Impact |
|---|---|---|---|
| In-house FFPE | 17-class | 0.988 AUC | Enables rapid, preliminary diagnosis across common cancers. |
| TCGA FFPE | 32-class | 0.964 AUC | Validates performance on diverse, public datasets, enhancing generalizability. |
| TCGA Frozen | 32-class | 0.950 AUC | Adapts to varied tissue preparation, crucial for broad clinical utility. |
PathOrchestra excels in identifying and analyzing lesions across multiple organs, supporting precise diagnosis, tumor detection, and cell segmentation. This capability streamlines pathologists' workflows and improves diagnostic efficiency.
0.923
Nuclear Segmentation Precision (PanNuke)
| Task Category | Key Metric | PathOrchestra Performance | Clinical Value |
|---|---|---|---|
| Metastasis Detection (WSI) | ACC/F1/AUC | ACC=1.0 (CAMELYON16), ACC=0.840 (CAMELYON17) | Automates detection of metastatic cancer cells, improving screening. |
| Cell Segmentation (Multi-organ) | Precision/Recall/Dice | P=0.929, R=0.868, D=0.931 (Gland Seg) | Provides precise quantification of cellular structures. |
| Nuclear Instance Segmentation | Precision/Recall/Dice | P=0.923, R=0.833, D=0.849 (PanNuke) | Critical for detailed cytopathological analysis. |
PathOrchestra delivers broad adaptability and high performance in classifying tumor subtypes across various cancers, supporting personalized treatment plans and accurate prognostic assessments.
1.000
Perfect Accuracy in Colorectal Subtype Classification
| Cancer Type | Task | PathOrchestra Performance (ACC/F1/AUC) | Impact |
|---|---|---|---|
| Bladder Cancer | Benign/Malignant Classification | ACC=0.954, F1=0.943, AUC=0.989 | Enhances early screening and diagnosis. |
| Lymphoma | Reactive Hyperplasia Classification | ACC=0.975, F1=0.941, AUC=0.994 | Aids in accurate lymphoma subtyping. |
| Colorectal Cancer | Subtype Classification (LC25K-2) | ACC=1.000, F1=1.000, AUC=1.000 | Achieves definitive subtype identification. |
| Lung Cancer | Subtype Classification (LC25K-3) | ACC=0.999, F1=0.999, AUC=0.999 | Supports precise classification for targeted therapies. |
PathOrchestra demonstrates robust performance in evaluating commonly used IHC markers, offering critical insights for tumor subtyping, prognosis, and treatment decisions, particularly in complex molecular evaluation tasks.
0.977+
High Accuracy in Key Biomarker Assessments
| Marker | Assessment Type | PathOrchestra Performance (ACC/F1) | Diagnostic Relevance |
|---|---|---|---|
| HER2 | Scoring | ACC/F1 > 0.920 | Critical for targeted breast cancer therapy. |
| CD20 | Qualitative Analysis | ACC/F1 > 0.920 | Essential for lymphoma diagnosis and classification. |
| PD-L1 | Expression Analysis | ACC/F1 > 0.800 | Guides immunotherapy decisions. |
| CyclinD1 | Expression Analysis | ACC/F1 > 0.800 | Supports assessment of cell proliferation. |
PathOrchestra significantly advances molecular pathology by accurately predicting gene expression profiles directly from H&E-stained images, outperforming existing foundation models in multiple cancer types.
6.5%
Higher Accuracy in PRAD Gene Prediction vs. UNI
| Cancer Type | Prediction Task | PathOrchestra vs. Others | Benefit |
|---|---|---|---|
| LUAD | Gene Expression | Superior to UNI and GigaPath | Identifies distinct gene expression patterns for lung cancer. |
| PRAD | Gene Expression | 6.5% higher ACC than UNI | Enhances molecular characterization of prostate cancer. |
| SKCM | Gene Expression | Superior to UNI and GigaPath | Provides insights into melanoma progression. |
| IDC | Gene Expression | 4.4% higher ACC than UNI | Supports personalized treatment for breast cancer. |
PathOrchestra pioneers the automatic generation of structured pathology reports for complex diseases like colorectal cancer and lymphoma, significantly reducing pathologist workload and standardizing diagnostic output.
Enterprise Process Flow: Structured Report Generation
HE Image Analysis
→
Subtype Prediction
→
IHC Marker Assessment
→
Integrated Diagnosis
→
Structured Report Generation
Case Study: Automated Lymphoma Subtyping
PathOrchestra successfully integrates HE image analysis with 29 IHC marker qualitative assessments to diagnose lymphoma subtypes. This multi-modal approach generates comprehensive diagnostic explanations, as demonstrated in patient examples. While some data loss during collection can affect individual marker predictions, the overall diagnostic framework provides robust, clinically valuable reports.
Case Study: Colorectal Cancer Screening & Grading
The model accurately screens for colorectal cancer, distinguishes tumor from non-tumor tissues, and classifies tumor grades (low-grade, high-grade). For negative cases, it further classifies polyp types. This capability streamlines initial reporting, as seen in a patient diagnosed with high-grade intraepithelial neoplasia based on the model’s assessment.
Calculate Your Potential ROI with PathOrchestra
Estimate the efficiency gains and cost savings for your pathology department by adopting AI-powered image analysis.
Estimated Annual Savings
Annual Hours Reclaimed
Our Proven Implementation Roadmap
A structured approach to integrate PathOrchestra seamlessly into your existing operations and maximize its impact.
Pilot Program & Integration
Initiate a focused pilot within a specific pathology department. Integrate PathOrchestra into existing digital pathology workflows for a selected set of diagnostic tasks, gathering initial performance data.
Performance Validation & Customization
Rigorously validate AI performance against human expert consensus on pilot tasks. Customize PathOrchestra models to align with your institution's unique data characteristics and specific clinical needs.
Scalable Deployment & Training
Deploy PathOrchestra across multiple departments or facilities. Conduct comprehensive training programs for pathologists and lab staff on effectively utilizing AI-generated insights and reports.
Continuous Optimization & Expansion
Monitor real-world performance, gather ongoing feedback, and continuously refine the model's capabilities. Explore expansion to new diagnostic areas and integration with multimodal patient data for holistic insights.
Ready to Orchestrate Your Pathology Future?
Connect with our AI specialists to discuss how PathOrchestra can revolutionize your diagnostic workflow and patient care.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat